医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Vietnam Ministry of Health and Quintiles Collaborate to Advance Clinical Trial Excellence

2013年11月20日 AM11:25
このエントリーをはてなブックマークに追加


 

SINGAPORE

The Vietnam Ministry of Health’s Administration of Science, Technology and Training (ASTT) has signed an agreement with Quintiles to enhance clinical research in this growing nation of 90 million people, Quintiles announced today.

This collaboration marks a new stage in the ministry’s efforts to support the development of new, better therapies for diseases that afflict the populations of Vietnam and Southeast Asia, said ASTT Director Prof. Nguyen Cong Khan, M.D., Ph.D.

“Quintiles knows how to conduct clinical research to global standards and its experts understand Asia and Vietnam,” Prof. Khan said. “By sharing their knowledge and insights, Quintiles can help us develop and execute a long-term plan for improving the quality, scope and breadth of clinical research in Vietnam.”

Under the two-year agreement, Quintiles and ASTT will collaborate in forming a larger working group to address a variety of topics, including improved processes for trial management; development of streamlined processes to improve trial efficiency and quality; and training for investigators and ethics committees.

“We’ve been working with the ministry to provide investigator training and site development since first establishing a presence in Vietnam in 2005,” said Ross Horsburgh, M.D., who leads Quintiles’ operations in Southeast Asia, Taiwan, South Korea, Australia and New Zealand. “This agreement deepens our commitment to developing medicines here to fight tropical and infection diseases and other conditions that afflict populations in Vietnam and Southeast Asia.”

Quintiles Vietnam LLC has offices in Ho Chi Minh City and Hanoi.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 28,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

CONTACT

Quintiles
Jessie Lee, Media Relations, +65.6602.1576 (office)
+65.8181.3805 (mobile)
jessie.lee@quintiles.com
or
Karl
Deonanan, Investor Relations, +1.919.998.2789
InvestorRelations@quintiles.com
www.quintiles.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • P&G Sets New Goal to Deliver 25 Billion Liters of Clean Drinking Water to Families in Need Worldwide
  • Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  • Takeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
  • オクタファルマ・グループが2018年の好業績を発表
  • 香港贸发局香港国际医疗及保健展尖端医疗科技及保健产品 迎合采购所需